Experiencing Agitation with Alzheimer’s Disease?
Explore Alzheimer’s-Related Agitation Clinical Trials Investigating Novel Treatment Options!
Alzheimer’s disease is the most common form of dementia. It is a neurodegenerative disorder that leads to morbidity and eventual mortality. Agitation in Alzheimer’s patients, aggression, hallucination, and delusions are estimated to affect 90% of people with Alzheimer’s disease, with an increasing prevalence as the disease progresses.
At present, there are no FDA-approved treatments for symptoms of agitation in Alzheimer’s patients. As a result, people with symptoms of agitation in Alzheimer’s disease are often treated with off-label antipsychotics, which result in a functional decline with Alzheimer’s disease. Revive Research Institute is conducting paid Alzheimer’s-Related Agitation Clinical Trials for agitation symptoms and investigating potential treatment options.
You may qualify for the paid Agitation Associated with Alzheimer’s Dementia Clinical Study if you:
- Are between 50 to 90 years of age
- Have been diagnosed with Alzheimer’s disease
- Have moderate to severe agitation for at least 2 weeks
*Additional criteria may apply
*Take part in paid Alzheimer’s-Related Agitation Clinical Trials at no cost to you or your private medical insurance. You will be reimbursed financially for your time and travel. In addition, all participants receive study-related care from an experienced research team.
*If you are interested in participating in the Alzheimer’s-Related Agitation Clinical Trials or would like more information, please fill out the form so we can determine if you qualify for the study and can contact you. Note that this is an entirely voluntary decision.